In vitro inhibition of ABCG2- and ABCC1-mediated daunorubicin and mitoxantrone efflux was demonstrated also by talazoparib, a drug approved for metastatic BCRA1/2 mutated breast cancer [149]. Here, ABCG2 is linked to breast cancer.